Melanotan II vs Bremelanotide

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

Melanotan II: FBremelanotide: A

Attribute	Melanotan II	Bremelanotide
Category	Melanocortin Agonist	Sexual Health
Evidence Rating	F — No Regulatory Activity	A — FDA Approved
Clinical Status	Research-only / Not approved. Multiple regulatory warnings issued worldwide.	FDA-approved (Vyleesi for premenopausal HSDD, June 2019)
Mechanism	MT-II activates melanocortin receptors MC1R through MC5R non-selectively. MC1R activation stimulates melanogenesis (skin tanning) in melanocytes. MC3R/MC4R activation in the CNS increases sexual arousal and desire via dopamine release pathways. MC4R activation centrally suppresses appetite. The non-...	Bremelanotide activates melanocortin 4 receptors (MC4R) and melanocortin 3 receptors (MC3R) in the central nervous system, particularly in hypothalamic nuclei involved in sexual arousal and desire. Unlike phosphodiesterase inhibitors that act on peripheral blood flow, bremelanotide acts centrally to...
Half-Life	~36 minutes IV; longer SC due to depot effect	~2.7 hours
Bioavailability	—	~100% subcutaneous
Molecular Weight	~1024.2 g/mol	~1025.2 g/mol
WADA Status	Prohibited	Not Listed
Dosing	Loading: 0.25–0.5 mg/day for 5–7 days; Maintenance: 0.5–1.0 mg 1–2x weekly, Daily during loading phase; 1–2x weekly maintenance (Subcutaneous)	1.75 mg, As needed, at least 45 minutes before anticipated sexual activity (Subcutaneous injection (autoinjector))
Key Use Cases	Tanning Sexual Health	Sexual Health Women's Health
Safety Concerns	Nausea (very common, especially at initial doses) Facial flushing and warmth Spontaneous erections (in males)	Common (>=5%): nausea (40%, typically mild-moderate and decreases with subsequent doses), flushing (20%), injection site reactions (13%), headache (11%) Transient increase in blood pressure: systolic +3 mmHg, diastolic +2 mmHg within 12 hours of dosing; resolves within 12 hours Skin hyperpigmentation: reported in 1% of patients, particularly in areas of darkly pigmented skin; mechanism related to MC1R cross-activation. May not fully resolve after discontinuation
Contraindications	History of melanoma or atypical moles/dysplastic nevi Cardiovascular disease Pregnancy and breastfeeding Family history of skin cancer	Uncontrolled hypertension or known cardiovascular disease (transient blood pressure elevation) Concurrent use with naltrexone or naltrexone-containing products (melanocortin pathway interaction reduces efficacy) Hypersensitivity to bremelanotide or any component Not indicated for use in men or postmenopausal women
Regulatory (US)	Not FDA-approved. FDA has issued warnings against use. Removed from Category 2 on April 15, 2026. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility.	FDA-approved (Vyleesi, June 2019) for premenopausal HSDD. Schedule not controlled.

Shop Melanotan II

View Melanotan II Product

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All Comparisons Browse Catalog

Melanotan II vs Bremelanotide

Explore MoreComparisons

Your Cart

Explore More
Comparisons